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ABSTRACT
In newly diagnosed multiple myeloma (MM), patients ineligible for front-line autologous stem cell
transplantation (ASCT), melphalan and prednisone (MP) with thalidomide (MPT) or bortezomib
(VMP) are standard first-line therapeutic options. Despite new treatment regimens incorporating
bortezomib or lenalidomide, MM remains incurable. The FIRST study demonstrated significant
improvement in progression-free survival (PFS) and overall survival (OS) for the combination of
lenalidomide and low-dose dexamethasone (Rd) until progression vs. MPT in transplant-ineligible
ndMM patients. However, to date no head-to-head randomized controlled trials (RCTs) have com-
pared Rd or MPT versus VMP. We conducted a network meta-analysis using RCTs identified
through a systematic literature review to evaluate the relative efficacy of Rd versus other regi-
mens on survival endpoints in previously untreated MM patients ineligible for ASCT. In this ana-
lysis, Rd was associated with a significant PFS and survival advantage versus other first-line
treatments (VMP, MPT, MP), challenging the role of alkylators in this setting.
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Introduction
Multiple myeloma (MM) is currently one of the most
common hematological malignancies, mainly affecting
individuals over 65 years of age.[1] In recent years, the
introduction of new therapeutic options coupled with
advances in the molecular understanding of the dis-
ease have improved patient survival; however, MM
remains incurable.[2]
High-dose chemotherapy paired with autologous
stem cell transplantation (ASCT) is the standard front-
line treatment for younger and fit patients with newly
diagnosed MM (ndMM). However, in patients who are
ineligible for ASCT due to age/frailty, comorbidities,
impaired fitness or disability, or who are otherwise
unwilling/unable to receive transplant, melphalan and
prednisone (MP) combined with either thalidomide
(MPT) or bortezomib (VMP) are current standard first-
line therapeutic options,[3] whose prescribing frequen-
cies vary by country. This includes, in some cases,
patients who are eligible for ASCT, but the treating
physician or patient instead choose a therapeutic
option, potentially postponing ASCT.[4]
New treatment combinations incorporating prote-
asome inhibitors and immunomodulatory drugs are
challenging the role of alkylators in ndMM treatment.
For instance, lenalidomide (R) combined with low-dose
dexamethasone (Rd) is an effective therapeutic option
for these patients and is an approved therapeutic
option by the US Food and Drug Administration and
European Medicines Agency. The phase III MM-020
(FIRST) trial, a randomized, open-label, three-arm study
determined the efficacy and safety of Rd versus MPT in
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transplant-ineligible ndMM patients and demonstrated
that Rd treatment until progression significantly
improved progression-free survival (PFS) and overall
survival (OS) compared with the MPT regimen.[5]
However, there are currently no direct head-to-head
clinical trials of Rd or MPT versus VMP, another com-
monly used regimen for the treatment of ndMM.
Head-to-head randomized controlled trials (RCTs)
are considered the gold standard approach for com-
paring the efficacy of different interventions, but are
not always available for all treatment options of inter-
est, especially as new treatments enter the market.
Network meta-analysis (NMA) is a statistical method to
simultaneously evaluate the comparative efficacy of
multiple treatment options through the use of direct
and indirect comparisons. This method allows for a
robust comparison of treatments that have not been
compared head-to-head.[6–8] In this study, we con-
ducted a NMA of RCTs identified through a systematic
literature review (SLR) to evaluate the relative efficacy
of Rd versus VMP and other agents for the treatment
of newly diagnosed or previously untreated MM
patients ineligible for ASCT (referred to as ndMM
patients hereafter) used according to their recom-
mended dosing schedules as per European Summary
of Product Characteristics (SmPC).
Materials and methods
Systematic literature review
Articles published in English from 1 January 1988 to 28
May 2015 were reviewed to identify relevant RCTs eval-
uating safety and efficacy endpoints for ndMM
patients. The SLR adhered to established guidelines [9]
and was based on a study protocol developed specific-
ally for this review.
Eligibility criteria
Eligibility criteria were defined in terms of the popula-
tion, interventions, comparisons, outcomes, and study
design (PICOS) criteria. The study population of interest
was untreated adult MM patients aged 65 years or
older or not eligible for stem cell transplantation.
Studies with fewer than 10 patients per treatment arm
were excluded. Treatment regimens searched included:
lenalidomide, thalidomide, bortezomib, bendamustine,
or interferon, as monotherapy or part of a combination
therapy, or MP combination treatment. Comparators of
interest included placebo, any of the above-listed inter-
ventions at a different dose or duration, or any other
active drug provided as monotherapy or as part of a
combination therapy. Outcomes of interest included:
PFS, OS, and safety (grade 3/4 adverse events [AEs],
serious adverse events [SAEs], and discontinuations
due to AEs). Fully published RCTs as well as conference
abstracts presenting the results of RCTs were consid-
ered eligible for inclusion.
Literature search strategies
Literature searches were conducted in Medline,
Embase and the Cochrane Central Register of
Controlled Trials. Additionally, we manually searched
conference proceedings from the following meetings
occurring between January 2013 and June 2015 to
identify additional relevant conference abstracts: ASCO,
ASH, EHA, ESMO and IMW. A manual check of the bib-
liographies of recent relevant reviews and meta-analy-
ses ensured optimal and complete literature retrieval.
The specific terms used in the database searches are
provided in the Supplementary Information.
Study selection
All abstracts were independently screened by two
investigators. Those eligible for inclusion were selected
for full text screening and independent review.
Discrepancies were resolved by involving a third inves-
tigator and reaching consensus. Articles meeting crite-
ria at the full-text stage were included in the analysis.
When multiple publications and/or conference
abstracts reported on a single trial population, only the
most recent or relevant data for the analyses were
selected for inclusion in the SLR.
Data collection process and data items
Study-level data, patient characteristics, treatment
details, and efficacy and safety endpoints were
extracted from the included trials. Data were also
extracted on length of follow-up and study inclusion
criteria. Hazard ratios (HRs) were extracted for OS and
PFS endpoints. When HRs were not available, these val-
ues were estimated as described in Tierney et al. [10]
When HRs were given but confidence intervals (CIs)
were not reported, these were estimated by using p
values and their corresponding Z-score to calculate the
standard error. When only number, probability, or pro-
portions of patients alive were reported, HR and 95%
CI were estimated using formulas based on the log-
rank test.
Risk of bias in individual studies
The Cochrane Collaboration’s tool for assessing risk of
bias in randomized trials was used.[11] This assessment
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was conducted by two investigators working inde-
pendently. Any differences were resolved through dis-
cussion with a third reviewer.
Analysis
Overview
A NMA was conducted on HRs for OS and PFS to
determine the comparative efficacy of treatments in
ndMM patients. Trials identified by the SLR were eli-
gible for inclusion in the statistical analysis if they
reported HRs for these survival endpoints. In order
to compare VMP with Rd using MPT and MP regi-
mens as common comparators, study comparability
and treatment relevance were assessed. The primary
analysis was limited to trials with a dosing schedule
in line with the respective regimens’ Summary of
Product Characteristics (SmPC) in order to minimize
heterogeneity and provide evidence approximating
actual use of the interventions of interest (fixed dur-
ation of treatment for MP, MPT, and VMP; treatment
until progression for Rd).[12–14] A sensitivity analysis
included all trials that were connected by one- or
two-degree linkages and formed a closed loop with
melphalan, prednisone and continuous thalidomide
(MPT-T).
Network meta-analysis
Network meta-analyses were performed in the Bayesian
framework using the standard procedures described by
the National Institute for Health and Care Excellence
(NICE) decision support unit.[15] Relative treatment
effects and modeled outcomes were summarized by
the median and 95% credible intervals (CrIs), con-
structed from the 2.5th and 97.5th percentiles. In this
SLR, the evidence networks consisted of a limited num-
ber of studies relative to the number of treatments
under consideration and nearly all connections in the
networks consisted of single trials. Additionally,
included studies comparing MPT versus MP, [16–18]
showed no heterogeneity (I2¼0%). Thus, a fixed effect
model was considered the most appropriate analysis.
The parameters of the different models were esti-
mated using a Markov Chain Monte Carlo method as
implemented in the OpenBUGS software package.[19,20]
All analyses were performed using OpenBUGS version
3.2.3 (OpenBUGS Project Management Group
Cambridge, UK, http://www.openbugs.net/w/FrontPage).
Celgene Corporation provided funding for the analysis
(Supplementary Information gives further statistical
details).
Results
Study selection
A total of 6550 abstracts were identified from the lit-
erature searches. After exclusion of 1450 duplicates,
5100 unique abstracts were eligible for review. Of the
unique abstracts, a further 4892 abstracts were
excluded from further review: 846 did not include a
population of interest; 179 did not investigate interven-
tions of interest; 54 did not report on outcomes of
interest; 1980 had an inappropriate study design; and
1833 abstracts were excluded due to other reasons
(such as being comments or review articles). Of the
208 full text articles screened and selected for further
review, 192 were excluded for the following reasons:
65 did not include a population of interest; 14 did not
evaluate an intervention or comparator of interest; 24
did not report on outcomes of interest; 54 had an
inappropriate study design; and 35 due to other rea-
sons. The resulting number of RCTs included was 16
(15 presented in full publications,[5,16–18,21–33] and
one presented in a conference abstract [34]). Two add-
itional publications were identified for inclusion
through manual searches of conference abstracts,
[21,29] for a total of 18 publications reporting on 17
trials.[5,16–18,21–36] A further two publications were
identified providing safety data not available in the
principal publications.[35,36] Of note, Fayers et al. was
excluded due to study design (meta-analysis); however,
this study provided HR data for Beksac et al. and
Waage et al. that was not otherwise available.[22,32,37]
A diagram of the study flow is presented in Figure 1(A).
Risk of bias
Overall, included trials presented minimal risk of bias.
The greatest risk of bias was posed by randomization
and allocation concealment. Details regarding method
of sequence generation for randomization were not
reported in two studies.[27,34] Further, allocation con-
cealment was only reported in 5 of 17 stud-
ies.[22,24–26,33] Inclusion/exclusion criteria were not
fully reported in one case due to the publication type
(abstract).[29] Although details on blinding were inad-
equately reported in a majority of studies, this is likely
due to ethical considerations surrounding the treat-
ment of MM. Baseline characteristics were presented in
all studies. Finally, all but three studies [22,23,29]
reported using the intention-to-treat population in
analyses (the risk of bias assessment Table of each
included trial is presented in the Supplementary
Information).
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Primary analysis network
Following review of the network and treatment charac-
teristics, several treatments were eliminated from inclu-
sion in the analysis based on clinical relevance and
treatment schedule. For example, only studies evaluat-
ing MPT received as fixed treatment duration were
included in the primary analysis (Table 1), in line with
treatment recommendations outlined in the current
SmPC for thalidomide.[14]
The primary analysis network was thus composed of
five trials evaluating Rd, VMP, MP and MPT (Figure 1(B)).
[5,16–18,21,30,36] Comparisons were evaluated using Rd
as the reference treatment. Baseline characteristics were
well distributed across trials, in terms of patient age and
disease severity (Table 2). Finally, endpoint analyses
were performed based on the intention-to-treat popula-
tion within trials.
Analyses of OS using fixed effects NMA models
documented a significantly lower risk of death with Rd
treatment until progression compared to all tested
treatment regimens (HRs [95% credible interval (CrI)]:
VMP, 0.66 [0.46–0.93]; MPT, 0.75 [0.62–0.90]; MP, 0.46
[0.34–0.60]) (Figure 2(A)). Similarly, a fixed effects ana-
lysis of PFS results showed a significantly lower risk of
progression or death with Rd treatment until progres-
sion compared to all tested treatment regimens (HR
[95% CrI]: VMP, 0.70 [0.49–0.99], MPT, 0.69 [0.59–0.80];
MP, 0.39 [0.31–0.50]) (Figure 2(B)). Of note, the HRs
and CrIs for MPT and VMP substantially overlapped for
both OS and PFS evaluations, suggesting little differ-
ence between these regimens, although direct compar-
isons were not made.
Sensitivity analyses
A sensitivity analysis was conducted on a broader net-
work of 11 trials to evaluate the effect of combining all
trials that evaluated MPT and MPT-T treatments as well
as any study comparator with a one- to two-degree
linkage to either of these treatments in the network.
This analysis added six trials to the primary analysis,
including five arms assessing MPT-T, one assessing
MPR, and two assessing MPR-R (Table 1, Figure 1(C)).
The sensitivity analysis for OS indicated a higher
level of heterogeneity, as the CrIs were somewhat
wider compared with the primary network analysis,
although all HR values significantly favored Rd (Figure
3(A)). This analysis showed a significantly lower risk of
death with Rd dosed until progression compared with
all other investigated interventions, including MP, MPT,
MPR, MPR-R, MPT-T, and VMP (HR [95% CrI]): MP 0.46
[0.34–0.60]; MPT 0.75 [0.62–0.90]; MPR 0.38 [0.23–0.60];
MPR-R 0.47 [0.31–0.71]; MPT-T: 0.46 [0.33–0.64]; VMP
0.66 [0.46–0.93]. In terms of PFS, the sensitivity analysis
also showed that all HR values significantly favored Rd,
Figure 1. Methodology figures. (A) Study selection for meta-analysis. CENTRAL, Cochrane Central Register of Controlled Trials. (B)
Network diagram including studies with similar MPT doses and schedules in the primary analysis network. (C) Network diagram for
sensitivity analysis of MPT and MPT-T studies and studies with 1- to 2-degree linkages. MP: melphalan and prednisone; MPR: mel-
phalan and prednisone with lenalidomide; MPR-R: melphalan and prednisone with lenalidomide followed by lenalidomide mainten-
ance; MPT: melphalan and prednisone with thalidomide; MPT-T: melphalan and prednisone with thalidomide followed by
thalidomide maintenance; Rd: lenalidomide and low-dose dexamethasone; VMP: melphalan and prednisone with bortezomib.
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including MP, MPT, MPR, MPR-R, MPT-T, and VMP (HR
[95% CrI]): MP 0.39 [0.31–0.50]; MPT 0.69 [0.59–0.80];
MPR 0.39 [0.26–0.58]; MPR-R 0.64 [0.46–0.89]; MPT-T:
0.60 [0.45–0.79]; VMP 0.70 [0.49–0.99] (Figure 3(B)).
An additional sensitivity analysis was conducted
evaluating all 17 trials identified from the systematic
literature search (Table 1). This analysis demonstrated a
statistically significant lower risk of death with Rd treat-
ment until progression compared to all thalidomide- or
bortezomib-based regimens, regardless of treatment
duration (data not shown).
Discussion
The availability of new combination regimens including
the novel agents’ thalidomide, bortezomib, and lenalido-
mide, has improved treatment options in ndMM
patients. In the absence of available RCTs directly com-
paring Rd versus VMP, the clinical decision-making pro-
cess can be complex. In such a situation, NMAs can be
useful. The present NMA results indicate that the Rd
regimen is a more effective treatment option for ndMM
patients ineligible for transplantation compared with
melphalan-containing regimens VMP, MPT and MP.
These results reinforce the improved OS and PFS benefit
reported for Rd directly compared with MPT.[5] In terms
of clinical decision-making, these results are meaningful,
since the Rd doublet therapy shows superior efficacy to
VMP and MPT triplet therapies, and to MP.
Moreover, Rd is a fully oral, alkylator-free regimen
that avoids/reduces risk of some grade 3/4 AEs associ-
ated with oral melphalan and triplet therapies, such as
peripheral neuropathy, fatigue, and gastrointestinal AEs
(diarrhea) with VMP [30,36] or infection, fatigue, per-
ipheral neuropathy, neurotoxicity, gastrointestinal AEs
(diarrhea, constipation), and venous thromboembolism
with MPT.[5,16–18,33,38,35] Although no NMA was
conducted on safety outcomes, the proportion of
patients discontinuing treatment due to AEs and the
Table 1. Extracted data from RCTs in the primary analysis and sensitivity analysis networks.
Study Group [Reference] Comparison (N patients) OS HR (95% CI) PFS HR (95% CI)
Primary analysis
MM-020 (FIRST) [5,21] Rd (535) versus MPT (547) 0.75 (0.62–0.90) 0.69 (0.59–0.80)
IFM 99/06 [16] MPT (125) versus MP (196) 0.59 (0.46–0.81) 0.51 (0.39–0.66)
IFM 01/01 [17,37] MPT (113) versus MP (116) 0.68 (0.48–0.96)a 0.62 (0.47–0.82) a
VISTA [30] VMP (344) versus MP (338) 0.70 (0.57–0.85) 0.56 (0.43–0.72)
Sacchi et al., 2011 [18] MPT (64) versus MP (54) 0.42 (0.18–0.98)a 0.67 (0.38–1.18)b
Additional studies in sensitivity analysis
TMSG [22,37] MPT-T (58) versus MP (57) 0.86 (0.46–1.60)d 0.70 (0.42–1.17)d
GIMEMA [26,37] MPT-T (167) versus MP (164) 1.04 (0.76–1.44) 0.63 (0.48–0.81)
MM-015 [28] MPR (153) versus MPR-R (152) 1.27 (0.85–1.89)a 2.04 (1.43–2.94)a
MP (154) versus MPR-R (152) 1.05 (0.69–1.60)a 2.50 (1.75–3.57)a
EIA06 [34] MPT-T (154) versus MPR-R (152) 1.00 (0.67–1.50)c 0.84 (0.64–1.09)
NMSG [32,37] MPT-T (182) versus MP (175) 1.12 (0.85–1.47)d 0.89 (0.70–1.13)d
HOVON 49 [33,37] MPT-T (165) versus MP (168) 0.84 (0.61–1.16)b 0.54 (0.38–0.76)b
Additional studies in full sensitivity analysis
IFM 95/01 [23] MD (118) versus MP (122) D (127)
versus MP (122) D-IFN (121) versus
MP (122)
0.85 (0.62–1.17)b 1.14 (0.84–1.55)b
1.10 (0.80–1.50)b
0.86 (0.65–1.13)b 1.70 (1.30–2.22)b
1.46 (1.12–1.92)b
GEM05 [24] VMP (130) versus VTP (130) 1.20 (0.60–2.40) 1.20 (0.90–1.70)
MRC Myeloma IX [25] MP (423) versus CTD (426) 0.89 (0.74–1.08) 0.82 (0.70–0.96)
Palumbo et al. [27] VMPTþ VT (254) versus VMP (257) 0.70 (0.52–0.92) 0.58 (0.47–0.71)
Palumbo et al. [29] MPR/CPR (430) versus Rd (211) 0.93 (0.60–1.41) 0.86 (0.66–1.12)
San Miguel et al. [31] VMPþ S (52) versus VMP (54) 1.00 (0.33–3.00)c 1.00 (0.58–1.75)b
CTD: cyclophosphamide, thalidomide, and dexamethasone; D: dexamethasone; D-IFN: dexamethasone and interferon; MP: melphalan and prednisone; MPR/
CPR; melphalan, prednisone, and lenalidomide or cyclophosphamide, prednisone, and lenalidomide; MPT: melphalan, prednisone, and thalidomide; MPTþ T;
melphalan, prednisone, and continuous thalidomide; MPR; melphalan, prednisone, and lenalidomide; MPRþ R; melphalan, prednisone, and continuous lena-
lidomide; Rd; lenalidomide and dexamethasone; VMP: bortezomib, melphalan, and prednisone; VMPþ S; bortezomib, melphalan, prednisone, and siltuximab;
VMPTþ VT: melphalan, prednisone, and continuous bortezomib and thalidomide; VTP: bortezomib, thalidomide, prednisone.
aConfidence interval estimated from p value.
bHazard ratio and confidence interval estimated from the Kaplan–Meier curve.
cHazard ratio and confidence interval estimated from number of deaths and survival rate.
dData obtained from meta-analysis [37].
Table 2. Summary of baseline patient characteristics from the
primary analysis network.
Study Treatment N
Age, median
(range)
ISS Stage III,
n (%)
MM-020 (FIRST) [5,21] Rd 535 73 (44–91) 216 (40.4)
MPT 547 73 (51–92) 224 (41)
IFM 99/06 [16] MP 196 (65–75) 54 (27.6)
MPT 125 (65–75) 32 (25.6)
IFM 01/01 [17,37] MP 116 (75–89) NR
MPT 113 (75–89) NR
VISTA [30] MP 338 71 (48–91) 115 (34)
VMP 344 71 (57–90) 119 (34.9)
Sacchi et al. [18] MP 54 79 (68–88) 16 (29.6)
MPT 64 76 (66–89) 14 (21.9)
ISS: international staging system; NR: not reported; MP: melphalan and
prednisone; MPT: melphalan, prednisone, and thalidomide; VMP: bortezo-
mib, melphalan and prednisone.
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reported grade 3/4 AEs from the 11 studies included
in the sensitivity analysis was overall higher in triplet
combinations compared with doublets.[16–18] Similar
results were observed in the FIRST trial, where 44% of
patients randomized to MPT reported grade 3/4
neutropenia compared with 28% in the Rd until pro-
gression group [5]. Where reported, grade 3/4 neuro-
pathic events were consistently higher in patients
receiving triplet versus doublet regi-
mens.[5,16–18,22,32,33,36,35] In terms of other non-
Figure 2. Mixed treatment comparison survival data: fixed effects analyses with Rd as reference. (A) overall survival (OS); (B) pro-
gression free survival (PFS). CrI: credible interval; HR: hazard ratio; MP: melphalan and prednisone; MPT: melphalan and prednisone
with thalidomide; Rd: lenalidomide and low-dose dexamethasone; VMP: melphalan and prednisone with bortezomib.
Figure 3. Mixed treatment comparison survival data: fixed-effects analyses with Rd as reference. (A) overall survival (OS); (B) pro-
gression free survival (PFS). CrI: credible interval; HR: hazard ratio; MP: melphalan and prednisone; MPR: melphalan and prednisone
with lenalidomide; MPR-R: melphalan and prednisone with lenalidomide followed by lenalidomide maintenance; MPT: melphalan
and prednisone with thalidomide; MPT-T: melphalan and prednisone with thalidomide followed by thalidomide maintenance; Rd:
lenalidomide and low-dose dexamethasone; VMP: melphalan and prednisone with bortezomib.
158 K. WEISEL ET AL.
hematological AEs, the most commonly reported grade
3/4 AE in patients randomized to Rd was infection, seen
in 29% of patients vs. 17% in MPT-treated patients. Most
cases of infection in the Rd group (80%) occurred in the
absence of neutropenia.[5]
Previously published indirect comparisons have
reported that both lenalidomide and bortezomib seem
to be more efficacious than thalidomide, and that add-
ition of these agents to MP is superior to MP alone in
ndMM patients. Indirect comparisons of lenalidomide
versus thalidomide maintenance after ASCT and MPR-R
versus MPT-T demonstrated a statistically significant
PFS benefit (p< 0.001 in both comparisons), but no
survival difference when using observation/placebo as
the common comparator. Data also indicated that the
discontinuation rate from thalidomide trials appeared
higher than in lenalidomide trials, suggesting that lena-
lidomide is less toxic than thalidomide.[39] Compared
with MPT, one indirect comparison analysis showed
that VMP statistically significantly prolonged both PFS
and OS (p< 0.001 in each case). However, the OS
benefit in the VMP group did not apply to elderly
patients (75 years).[40] Further, this previous analysis
excluded the VISTA trial of VMP versus MP,[36] used
for regulatory approval of VMP, as well as excluding
IFM 01/01 [17] and IFM 99/06,[16] all of which were
included in the present analysis. Two other studies
evaluating VMP versus MPT showed no difference in
survival outcomes.[41,42]
Meta-analyses are limited by the assumption that
trials and outcomes are similar enough for data pool-
ing. This assumption is given credibility by using spe-
cific pre-defined inclusion criteria during the systematic
review trial selection process, ensuring that the
retrieved trials show comparable patient populations
and clinically relevant endpoints. Although between-
study differences are inevitable, and heterogeneity in
the analysis may provide a measure of uncertainty in
effects due to differences in clinical practice, the cur-
rent NMA showed very little heterogeneity by includ-
ing only RCTs evaluating clinically relevant treatments
that reflect clinical practice. For example, we included
all studies identified from our literature search that
included MPT dosed according to SmPC dosing
description (i.e. for a fixed treatment duration). Further,
Cochrane’s risk of bias tool was also applied to ensure
study quality. Strict PICOS criteria also limited the risk
of bias due to inconsistency. Finally, the distributions
of baseline characteristics across trials were considered
sufficiently homogenous for inclusion in a single NMA.
Although missing survival data were imputed, most
imputations were done through calculations based on
Kaplan–Meier curves. The largest source of
inconsistency was the maturity of the studies at the
time points at which outcomes were reported, which
varied between 12 and 96 months of median follow
up. Based on the network size on which the analyses
were performed, the fixed effect analysis is considered
the most robust estimate of treatment effects.
In the current analyses, Rd treatment until progres-
sion was associated with a significant advantage in OS
and PFS compared with the first-line treatments VMP,
MPT and MP. The sensitivity analysis also showed a sig-
nificantly lower risk of death and progression with Rd
compared with all investigated interventions, including
MPR, MPR-R, and MPT-T. The results suggest that Rd
treatment until progression is likely the best treatment
option for untreated patients with ndMM ineligible for
stem cell transplantation and/or over 65 years of age.
The analysis did not allow for examination of patient
subgroups, such as ISS stage, age, renal impairment or
cytogenetically high-risk patients. We expect treatment
decisions continue to be made on an individual basis,
taking disease features and co-morbidities into consid-
eration; certain patient subgroups may better benefit
from one regimen over another. However, these data
are clinically important in a setting in which alkylating
agents have long been considered treatment stand-
ards. Of note, in addition to favorable efficacy and
safety parameters,[5] the Rd regimen has shown sig-
nificant improvements in clinically relevant quality of
life measurements,[43] which is of considerable value
in the context of elderly patients with an incurable dis-
ease such as MM.
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